NEW YORK (GenomeWeb News) – Genewiz today announced a deal with BeiGene for the use of Genewiz's cancer panels to accelerate cancer biomarker discovery.

Under the terms of the deal, Beijing-based BeiGene will use Genewiz's OncoGxOne Discovery cancer panels to identify and elucidate genetic variations in cancers that are prevalent in China and the Asia-Pacific region.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.